Part of the 13th annual RNA Therapeutic series of events
SMi’s 2^nd Annual Conference

Oligonucleotide Therapeutics and Delivery Conference 2022
Date: 21^st – 22^nd September 2022
Location: London, UK
Website: www.oligonucleotide.co.uk/PharmaJournalist

Advancements in extra-hepatic delivery of oligonucleotides

The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

Benefits of attending:

• Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials
• Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity
• Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development
• Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA
• Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics

Plus, two interactive half day pre-conference workshops on 20^th September 2022:

• Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator, Ritwick Sawakar, MRC Investigator, MRC Toxcology Unit, University Of Cambridge
• Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC Consulting 

CHAIRS FOR 2022:

• Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon
• jimmy Weterings, Principal Scientist, AstraZeneca 

FEATURED 2022 SPEAKERS INCLUDE:

• Shalini Anderson, Vice President Oligonucleotide Discovery,AstraZeneca
• Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech
• Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen pharmaceuticals
• SarahTabrizi,Director of UCL Huntington’s disease centre, UCL Institute of Neurology
• Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets
• David Evans, Chief Scientific Officer, Sirnaomics
• Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator
• Bart Anderson,Senior Director of R&D, Exicure

Who should attend:

Executives, Directors, VPs, Heads, Principals, Managers of:

• RNA Biology/Discovery
• Novel Therapeutic Modalities
• Innovation Technologies
• C-level Scientific Executives
• Formulation and Drug Delivery
• Clinical Research and Development
• Cell Biology

EARLY-BIRD RATES:

• BOOK BY 29^TH APRIL AND SAVE £400
• BOOK BY 31^ST MAY AND SAVE £300
• BOOK BY 30^TH JUNE AND SAVE £200

Additional Contact Info:

T: +44 (0)20 7827 6154

E: ngaloria@smi-online.co.uk

LinkedIn: SMi Pharma

Twitter: @SMiPharma | #SMiOligonucleotides 

Keywords:

Small interfering RNA, siRNA, Antisense therapy, DNA, RNA, nucleic acid, mRNA, Micro RNA, RNA-induced silencing complex, RISC, Aptamers, oligonucleotide, peptide molecules, Immunogenicity, Drug pipeline, short interfering RNA, silencing RNA, RNA interference, RNAi, mRNA degradation

Hashtags:

#SmallinterferingRNA, #siRNA, #Antisensetherapy, #DNA, #RNA, #nucleicacid, #mRNA, #MicroRNA, #RNAinducedsilencingcomplex, #RISC, #Aptamers, #oligonucleotide, #peptidemolecules, #Immunogenicity, #Drugpipeline, #shortinterferingRNA, #silencingRNA, #RNAinterference, #RNAi, #mRNAdegradation